WO1993023010A1 - Ophthalmic compositions containing a cyclosporin - Google Patents
Ophthalmic compositions containing a cyclosporin Download PDFInfo
- Publication number
- WO1993023010A1 WO1993023010A1 PCT/EP1993/001123 EP9301123W WO9323010A1 WO 1993023010 A1 WO1993023010 A1 WO 1993023010A1 EP 9301123 W EP9301123 W EP 9301123W WO 9323010 A1 WO9323010 A1 WO 9323010A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclosporin
- eye
- ophthalmic composition
- composition according
- ophthalmic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to ophthalmic compositions, particularly eye-drop formulations, comprising a cyclosporin as active ingredient and being suitable for the 5 treatment of diseases of the eye and surrounding areas.
- the cyclosporins comprise a large and recognized class of peptide compounds having pharmaceutical utility, for example immunosuppressant, anti-inflammatory, and/or anti-parasitic activity and/or activity in abrogating tumor resistance to anti-neoplastic or cytostatic drug therapy.
- the cyclosporins include, for example, naturally occurring fungal 0 metabolites, such as the cyclosporin A, B, C, D and G, as well as a wide variety of synthetic and semi-synthetic cyclosporins, for example the dihydro- and iso-cyclosporins (see e.g.
- cyclosporin A is commercially available under the Registered Trade Mark SANDIMMUN or 0 SANDIMMUNE. Cyclosporin A has been shown to suppress selectively a variety of
- T-lymphocyte functions including prevention of maturation and expression of sensitized T-lymphocytes in cell mediated immune responses, and is now successfully and widely used in the suppression of organ transplant rejection.
- Cyclosporin A has also been used systemicallv in the treatment of intraocular inflammatory or autoimmune diseases, such as 5 uveitis.
- Cyclosporin A has also been used systemicallv in the treatment of intraocular inflammatory or autoimmune diseases, such as 5 uveitis.
- Cyclosporin A has also been used systemicallv in the treatment of intraocular inflammatory or autoimmune diseases, such as 5 uveitis.
- Eye-drops which are acceptable to the eye. Eye-drops are required which do not cause patient discomfort and which permit a convenient administration regimen and do not require unduly frequent administration, while providing adequate drug substance delivery both to the external and, in particular, the internal regions of the eye.
- a fu ⁇ her difficulty is the very poor solubility of cyclosporin A in water. This leads often to precipitation of cyclosporin A from aqueous-based eye-drops causing strong irritation of the eye.
- this invention provides an ophthalmic composition comprising a cyclosporin, especially cyclosporin A, and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers, and polyoxyethylene alkyl ethers, or mixtures thereof.
- the ophthalmic compositions are preferably formulated as eye-drop formulations. Preferably they are aqueous based.
- Preferred polyoxyethylene fatty acid esters are based on saturated fatty acids, preferably not containing any substituent.
- the chain length may be from 14 to 22 carbon atoms, preferably 16 to 18 carbon atoms.
- a preferred fatty acid is stearate.
- the ester is a mono ester.
- the polymerization number of the polyoxyethylene moiety is from about 20 to about 60.
- a preferred example is polyoxyl 40 stearate.
- An example is the polyoxyl 40 stearate known under the brand name Myrj 52 (available from Atlas Chemie, Essen, Germany).
- Preferred polyoxyethylene aralkyl esters are based on a phenol substituted by one or more alkyl groups; the alkyl groups for example having from 4 to 10 carbon atoms, preferably 8 or 9 carbon atoms.
- the phenyl group has only one alkyl group as substituent.
- the polymerization number of the polyoxyethylene moiety is from about 1 to about 50, more preferably around 40.
- CTFA Cosmetic. Toiletry & Fragrance Association, Inc
- Examples are octoxynols, for example those known under the brand name "Triton” and obtainable from Rohm and Haas. Philadelphia, USA.
- the weight ratio of surfactant to cyclosporin is from about 10:1 to about 50:1.
- the concentration of surfactant in the ophthalmic compositions is desirably within the range of from about 0.1 % to about 3.0 % (w/v), and, more desirably from about 0.15 to about 2.5 % (w/v), and especially 0.75% to 2.5% (w/v).
- Suitable polyvinyl polymers are poly vinylacetates and poly vinylalcohols and suitable polyvinylpyrrolidones are poly-N- vinylpyrrolidones and vinylpyrrolidone co-polymers such as vinylpyrrolidone-vinylacetate co-poiymers.
- the concentration of the thickening agents to be used is not critical. Typically it is within the range of about 0.05 to about 5.0 % (w/v), and more desirably, from about 0.1 to about 3.0 % (w/v).
- ophthal ic compositions it is possible to obtain sufficient therapeutic efficacy of cyclosporins A in the eye-drops even at low concentrations of cyclosporins in the composition.
- the anti-oxidant should be present at concentrations below which it causes irritation of the eyes.
- concentration of anti-oxidant should be within the range 20 from about 0.00005 to about 0.1 % (w/v), more desirably within the range of from about
- the prefe ⁇ ed ophthalmic composition comprises from about 0.01 to about 0.075 %
- cyclosporin A from about 0.15 to about 2.5 % (w/v) of polyoxyl 40 stearate; from about 0.1 to about 3.0 % (w/v) of a cellulose thickening agent selected from 25 hydroxypropyl methylcellulose or hydroxyethylcellulose; and from about 0.0001 to about
- ethanol is present, for example at a concentration of about 0.01 to 0.5% (w/v).
- the pH of the ophthalmic composition may be within the range which is normally used for ophthalmic preparations, but is desirably within the range of 4 to 8.
- the ophthalmic compositions may be prepared by mixing the cyclosporin with the above-mentioned surfactant, and as desired mixing in the thickening agent and the anti-oxidant, and other excipients.
- this invention provides an ophthalmic composition as defined above in a container appropriate for ophthalmic application of the composition, for example appropriate for application of the ophthalmic composition to or at the surface of the eye (for example to the cornea or comeal epithelium).
- the invention also provides a method of treating a disease or condition of the eye or of the su ⁇ ounding or associated organs or tissues, in a subject in need thereof, in particular of treating immune mediated or inflammatory diseases organs or tissues, which method comprises administering an ophthalmic composition as defined above topically to the eye, for example to or at the surface of the eye (for example to the comea or corneal epithelium).
- the pa ⁇ icular sections , segments or tissues of the eye to which the method is applicable are as described in this specification. Particular diseases or conditions of the eye to which the method is applicable are similarly as described in this specification.
- the invention provides an ophthalmic composition as defined above for use in a method as defined above.
- this invention provides the use of a cyclosporin in the preparation of an ophthalmic composition for use in a method as defined above.
- the following examples are illustrative of ophthalmic compositions of the invention. Further details of components are given in "Lexicon for Pharmazie, Kosmetic and angrenzende füre" by H. P. Fiedler, 3rd Edition, 1989 published by Editio Cantor Aulendorf, Germany; Handbook of Pharmaceutical Excipients, 1st Edition, 1986, joint publication of American Pharmaceutical Association, Washington, USA and the
- viscosity is measured as Newton viscosity at 25°C, for example measured in a viscosity measuring apparatus type CV 20 produced by HAAKE.
- the polyoxyl 40 stearate used in the Examples is KIKKOL (Registered Trade
- MYS-40 a product of Nikko Chemicals Co. Ltd. Japan. It has a congealing point of 39 to 44°C, an acid value of not more than 1 and a saponification value of 25 to 35.
- the polyoxyethylene octyl phenyl ether used in the Examples is NONION HS 240, a product of Nippon Oil and Fats Co. Ltd., Japan.
- the mean polymerization number is 40 and the mean molecular weight is 1968.
- EXAMPLE 1 Eye-drop formulation (in 100 ml)
- the cyclosporin A is dissolved in an ethanolic solution containing the butylated hydroxytoluene, and the polyoxyl 40 stearate is added to it. After warming the mixture, the hydroxypropyl methylcellulose (which is dissolved in advance into a small amount of sterilized purified water) is added and the remaining sterile purified water is added to the mixture to yield a clear solution. Lastly, the sodium chloride, sodium dihydrogen phosphate and sodium edethate is added to the mixture, and the pH is adjusted to 6.0 using sodium hydroxide solution.
- the following formulations can be prepared in the same manner as mentioned above.
- EXAMPLE 2 Eye-drop formulation (in 100 ml)
- EXAMPLE 4 Eye-drop formulation (in 100 ml)
- polyoxyl 40 stearate may be replaced by an equivalent amount of polyethylene octyl phenyl ether or polyoxyethylene alkyl ether.
- the ophthalmic compositions are useful for the same indications as other topical ophthalmic compositions containing cyclosporins, for example diseases affecting the cornea, the aqueous, the lens, the iris, the ciliary, the choroid or the retina.
- the ophthalmic compositions are useful particularly for the treatment of an autoimmune or inflammatory disease or condition of the eye or of the surrounding or associated organs or tissues, that has undesirably elevated immuno-response or inflammatory reaction or event as pan of its etiology.
- the ophthalmic compositions are useful preferably for ⁇ reating the anterior or posterior segment of the eye.
- ophthalmic compositions may also be used in the treatment of immunoreactive graft rejection post corneal transplantation, Beh ⁇ et disease, and autoimmune corneal diseases such as Mooren's ulcer, ocular pemphigus, and rheumatoid ulcer.
- the utility of the ophthalmic compositions and advantageous therapeutic properties can be observed in standard animal models and in standard clinical tests; for example by administering, a few times a day, 0.05 ml to 0.5 ml, preferably 0.1 ml to 0.2 ml, of an ophthalmic composition containing 0.005% to 1.0%, preferably 0.01% to 0.5%, (by weight) of cyclosporin to the eyes of patients exhibiting diseases or conditions of the eye as set fo ⁇ h above.
- the tolerance of and transfer of the cyclosporin into the eye may be shown in tests as described below.
- the optimal dosage to be administered to a particular patient will vary from patient to patient and from disease to disease and must be considered carefully by the treating physician.
- doses in the range of 0.05 ml to 0.5 ml, preferably 0.1 ml to 0.2 ml, of an ophthalmic composition containing 0.005% to 1.0%, preferably 0.01% to 0.5%, (by weight) of cyclosporin may be used. Satisfactory results are obtained by administering droplets of about 0.05 ml a few times a day; for example 1 to 5 times a day.
- the excellent tolerance of the ophthalmic compositions may be determined in conventional tests.
- the compositions are administered topically to groups of 6 rabbits.
- One drop (about 50 microlitre) at a time is instilled intra-ocularly into one eye, every 30 minutes, for 5 hours (ten administrations).
- the other eye (untreated) is used as a control.
- the eye is then examined microscopically for irritation at 1, 5 and 18 hours after the final administration, and the effect of the composition judged with respect to: opacity and opaque area in the cornea; the iris, redness and edema of conjunctival palpebrae, redness of conjunctival bulbi, state of mictating membrane and secretion of conjunctiva.
- the ophthalmic compositions show excellent tolerability.
- the compositions of Examples 5 A and B showed a zero score in all the above mentioned evaluations, except for the evaluation of redness of conjunctival palpebrae. In this evaluation, however, only a marginal redness of conjunctival palpebrae was noted at 1 hour after final administration and the results are very close or identical to results obtained with physiological saline (0.9% sodium chloride).
- the transfer of Cyclosporin A into the cornea (without epithelium) from the ophthalmic compositions may be evaluated by conventional tests. In one test 50 microlitres of test solution are installed into the eyes of groups of 5 rabbits and the amount of Cyclosporin A in the cornea measured.
- the cornea is then homogenized in 1 ml methanol while cooling with ice and the homogenate centrifuged at 3000 rpm for 10 minutes at room temperature. The supernatant is collected. 1 ml methanol are added, the mixture subjected to Boltex treatment and then centrifuged again. The supernatants are combined, evaporated at 40°C to 50°C and 1 ml methanol is added to the residue. 50 microlitres of the solution are measured out and the amount of Cyclosporin A therein determined by standard radioimmunoassay procedures. The excellent transfer of Cyclosporin A into the cornea is for example shown by the composition of Example 5C in the above test. A mean value of 479.2 ng g (S.D. +/- 245.8) is observed.
- the ophthalmic compositions are suitably administered at or to the surface of the eye in individual amounts.
- the ophthalmic compositions are suitably administered at or to the surface of the eye in individual amounts.
- the ophthalmic compositions are suitably administered at or to the surface of the eye in individual amounts.
- the ophthalmic compositions are found to be well tolerated by subjects undergoing such therapy, with no significant or untoward irritation.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP51984293A JP3631490B2 (en) | 1992-05-13 | 1993-05-07 | Cyclosporine-containing ophthalmic composition |
DE69307505T DE69307505T2 (en) | 1992-05-13 | 1993-05-07 | OPTHALMIC COMPOSITIONS CONTAINING A CYCLOSPORIN |
EP93909919A EP0642332B1 (en) | 1992-05-13 | 1993-05-07 | Ophthalmic compositions containing a cyclosporin |
GR970400664T GR3022990T3 (en) | 1992-05-13 | 1997-04-01 | Ophthalmic compositions containing a cyclosporin. |
HK98103406A HK1004520A1 (en) | 1992-05-13 | 1998-04-23 | Ophthalmic compositions containing a cyclosporin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9210226.8 | 1992-05-13 | ||
GB929210226A GB9210226D0 (en) | 1992-05-13 | 1992-05-13 | Pharmaceutical compositions |
GB9224367.4 | 1992-11-20 | ||
GB929224367A GB9224367D0 (en) | 1992-11-20 | 1992-11-20 | Organic compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/767,610 Continuation US5951971A (en) | 1992-05-13 | 1996-12-17 | Ophthalmic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993023010A1 true WO1993023010A1 (en) | 1993-11-25 |
Family
ID=26300871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/001123 WO1993023010A1 (en) | 1992-05-13 | 1993-05-07 | Ophthalmic compositions containing a cyclosporin |
Country Status (14)
Country | Link |
---|---|
US (2) | US5951971A (en) |
EP (1) | EP0642332B1 (en) |
JP (2) | JP3631490B2 (en) |
KR (1) | KR100344083B1 (en) |
CN (1) | CN1074932C (en) |
AT (1) | ATE147619T1 (en) |
DE (1) | DE69307505T2 (en) |
DK (1) | DK0642332T3 (en) |
ES (1) | ES2098739T3 (en) |
GR (1) | GR3022990T3 (en) |
HK (1) | HK1004520A1 (en) |
SG (1) | SG45449A1 (en) |
TW (1) | TW279801B (en) |
WO (1) | WO1993023010A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
EP0868909A2 (en) * | 1997-03-14 | 1998-10-07 | Arturo Jimenez-Bayardo | Ophthalmic carrier solution |
US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
EP1142566A1 (en) * | 2000-04-07 | 2001-10-10 | Laboratoire Medidom S.A. | Compositions for ophtalmic use containing cyclosporin, hyaluronic acid and polysorbate |
WO2004096261A1 (en) * | 2003-05-02 | 2004-11-11 | Arturo Jimenez Bayardo | Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution |
WO2005049061A2 (en) * | 2003-11-20 | 2005-06-02 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
EP1889620A1 (en) * | 2005-06-09 | 2008-02-20 | Santen Pharmaceutical Co., Ltd | Eye drop containing roflumilast |
US8114959B2 (en) | 2003-06-03 | 2012-02-14 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
WO2013140071A1 (en) * | 2012-03-22 | 2013-09-26 | Laboratoires Thea | Cyclosporin a-based aqueous ophthalmic solution |
US8614181B2 (en) | 2003-06-03 | 2013-12-24 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
US8710181B2 (en) | 2004-08-31 | 2014-04-29 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
US8748376B2 (en) | 2004-11-12 | 2014-06-10 | Novo Nordisk A/S | Stable formulations of peptides |
US8846618B2 (en) | 2001-06-28 | 2014-09-30 | Novo Nordisk A/S | Stable formulation of modified GLP-1 |
KR20150100763A (en) * | 2012-12-19 | 2015-09-02 | 에스에이알코드 바이오사이언스 인코포레이티드 | Lfa-1 inhibitor formulations |
WO2016011449A1 (en) * | 2014-07-18 | 2016-01-21 | Allergan, Inc. | Suspension compositions of cyclosporin a for subconjunctival and periocular injection |
WO2016012912A1 (en) | 2014-07-25 | 2016-01-28 | Imuneks Farma Ilac Sanayi Ve Ticaret A.S. | Stable preservative free ophthalmic formulations of opioid antagonists |
EP3329940A4 (en) * | 2015-07-29 | 2019-01-02 | Kukje Pharm. Ind. Co., Ltd | Non-irritant ophthalmic composition containing cyclosporin, and convenient preparation method |
CN109906085A (en) * | 2016-09-23 | 2019-06-18 | 诺瓦利克有限责任公司 | Ophthalmic composition containing cyclosporine |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
US11752198B2 (en) | 2017-08-24 | 2023-09-12 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0642332B1 (en) * | 1992-05-13 | 1997-01-15 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
SG115386A1 (en) | 1997-01-30 | 2005-10-28 | Novartis Ag | Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil |
WO2000074649A2 (en) | 1999-06-03 | 2000-12-14 | Maxim Pharmaceuticals, Inc. | Ophthalmic histamine compositions and uses thereof |
JP4880808B2 (en) * | 1999-11-15 | 2012-02-22 | 久光製薬株式会社 | Artificial tear-type eye drop composition |
US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
US7241674B2 (en) * | 2004-05-13 | 2007-07-10 | Taiwan Semiconductor Manufacturing Co., Ltd. | Method of forming silicided gate structure |
US7151085B2 (en) * | 2004-11-15 | 2006-12-19 | Allergan, Inc. | Therapeutic methods using cyclosporine components |
US7135455B2 (en) * | 2004-11-15 | 2006-11-14 | Allergan, Inc | Methods for the therapeutic use of cyclosporine components |
CN101171000A (en) * | 2005-04-12 | 2008-04-30 | 依兰药物国际有限公司 | Nanoparticulate and controlled release compositions comprising cyclosporine |
US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7288520B2 (en) * | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US7501393B2 (en) | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
AU2006304143A1 (en) * | 2005-10-14 | 2007-04-26 | Allergan, Inc. | Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
EP1956906A4 (en) * | 2005-11-09 | 2009-12-30 | Combinatorx Inc | Methods, compositions, and kits for the treatment of medical conditions |
US20080146497A1 (en) * | 2006-07-25 | 2008-06-19 | Graham Richard S | Cyclosporin Compositions |
AU2016203191B2 (en) * | 2006-07-25 | 2018-03-01 | Allergan, Inc. | Cyclosporin compositions |
US9561178B2 (en) * | 2006-07-25 | 2017-02-07 | Allergan, Inc. | Cyclosporin compositions |
CN101896160A (en) * | 2006-10-17 | 2010-11-24 | 阿勒根公司 | Cyclosporin compositions |
DE202007008971U1 (en) | 2007-06-27 | 2008-11-06 | Weber, Erhard, Dr. | Foam spacers for filling mattress cores, upholstery and pillows |
EP2234629A4 (en) * | 2008-01-04 | 2011-05-25 | Alcon Pharmaceuticals Ltd | Stable aqueous cyclosporin compositions |
JP5288970B2 (en) * | 2008-09-26 | 2013-09-11 | シスメックス株式会社 | Method for measuring mean red blood cell volume using a reagent for diluting blood samples |
WO2010127301A1 (en) * | 2009-05-01 | 2010-11-04 | Allergan, Inc. | Method of treating allergic conjunctivitis with cyclosporin compositions |
JP5673531B2 (en) * | 2009-06-30 | 2015-02-18 | ライオン株式会社 | Ophthalmic composition |
US8501796B2 (en) | 2010-09-16 | 2013-08-06 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
CN103228283A (en) * | 2010-11-29 | 2013-07-31 | 千寿制药株式会社 | Oil-in-water emulsion composition containing difluprednate and tobramycin |
US9018202B2 (en) | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
DE102011108948A1 (en) * | 2011-07-29 | 2013-01-31 | Achim Göpferich | Aqueous, colloidal solutions of lipophilic substances, in particular drug solutions |
WO2013078151A1 (en) | 2011-11-21 | 2013-05-30 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
RU2014129268A (en) * | 2011-12-16 | 2016-02-10 | Аллерган, Инк. | OPHTHALMIC COMPOSITIONS THAT CONTAIN GRAVITY POLYVINYL POLYVINYL PROCALT-POLYVINYL ACETATE-POLYETHYLENE Glycol copolymers |
US20130197002A1 (en) | 2012-01-30 | 2013-08-01 | Allergan, Inc. | Brimonidine for treating visual disorders mediated by central visual projections from the eye |
KR101211902B1 (en) * | 2012-04-30 | 2012-12-13 | 주식회사 휴온스 | Non-irritating ophthalmic nano-emulsion composition comprising cyclosporin |
FI2887923T3 (en) * | 2012-08-24 | 2023-06-30 | Sun Pharmaceutical Ind Ltd | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
WO2014050301A1 (en) * | 2012-09-27 | 2014-04-03 | 千寿製薬株式会社 | Aqueous liquid medicine |
WO2014078766A1 (en) * | 2012-11-19 | 2014-05-22 | Bausch & Lomb Incorporated | Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
BR112017025631A2 (en) * | 2015-05-29 | 2018-08-07 | Oculis Ehf | aqueous ophthalmic compositions, method of inducing or enhancing tear formation, method of forming cyclosporin agglomerates a and use of cyclosporin a |
SG11201906729RA (en) * | 2016-02-29 | 2019-08-27 | Sun Pharma Global Fze | Topical cyclosporine-containing formulations and uses thereof |
EP3500344A4 (en) | 2016-08-19 | 2020-08-05 | Akrivista, LLC | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye |
US11583496B2 (en) * | 2016-10-12 | 2023-02-21 | PS Therapy Inc. | Drug vehicle compositions and methods of use thereof |
CN114376961A (en) | 2017-08-18 | 2022-04-22 | 阿克里维斯塔有限责任公司 | Methods of diagnosing and treating dry eye syndrome and compositions for treating human eyes |
EP3993807A1 (en) * | 2019-07-01 | 2022-05-11 | Oculis SA | Method for stabilizing the ph of an aqueous composition comprising a drug |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649047A (en) * | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
EP0294239A1 (en) * | 1987-06-04 | 1988-12-07 | Sankyo Company Limited | Cyclosporin-containing pharmaceutical composition |
GB2211848A (en) * | 1987-12-21 | 1989-07-12 | Sandoz Ltd | Orthorhomic ciclosporin crystals |
FR2636534A1 (en) * | 1988-09-16 | 1990-03-23 | Sandoz Sa | PHARMACEUTICAL COMPOSITIONS BASED ON CYCLOSPORINS |
FR2638089A1 (en) * | 1988-10-26 | 1990-04-27 | Sandoz Sa | NOVEL OPHTHALMIC COMPOSITIONS BASED ON CYCLOSPORINE |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB616190A (en) | 1945-11-06 | 1949-01-18 | Procter & Gamble | Improvements in application of low temperature inter-esterification or alcoholysis to glycerides |
FR1274354A (en) | 1956-03-10 | 1961-10-27 | Surfactants obtained from triglycerides and polyethylene glycol | |
GB1171125A (en) | 1966-06-08 | 1969-11-19 | Glaxo Lab Ltd | Improvements in or relating to Injectable Preparations |
US3947573A (en) * | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
US3954967A (en) | 1971-08-05 | 1976-05-04 | Vanguard Chemical Company, Inc. | Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds |
US3813345A (en) | 1971-08-05 | 1974-05-28 | Vanguard Chem Co Inc | Method of producing microcolloidal aqueous emulsions of unsaturated organic compounds |
US4029817A (en) * | 1973-09-24 | 1977-06-14 | Allergan Pharmaceuticals | Soft contact lens preserving solutions |
US4073943A (en) | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
US4146499A (en) | 1976-09-18 | 1979-03-27 | Rosano Henri L | Method for preparing microemulsions |
JPS53107408A (en) | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
DE2907460A1 (en) | 1978-03-07 | 1979-09-13 | Sandoz Ag | NEW RESORBABLE GALENIC COMPOSITIONS |
CH636013A5 (en) | 1978-03-07 | 1983-05-13 | Sandoz Ag | More readily absorbable pharmaceutical composition |
CH641356A5 (en) | 1979-02-27 | 1984-02-29 | Sandoz Ag | Pharmaceutical compositions containing cyclosporin |
NZ199915A (en) | 1981-03-11 | 1985-07-12 | Unilever Plc | Treating edible oils to raise melting point thereof |
FR2502951B1 (en) | 1981-04-06 | 1985-12-06 | Sandoz Sa | TOPICAL PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A MICRO-EMULSION |
BE895724A (en) | 1982-02-01 | 1983-07-28 | Sandoz Sa | NEW THERAPEUTIC USE OF DIHYDROCYCLOSPORIN D |
DE3225706C2 (en) | 1982-07-09 | 1984-04-26 | A. Nattermann & Cie GmbH, 5000 Köln | Liquid active ingredient formulations in the form of concentrates for microemulsions |
DE3235612A1 (en) | 1982-09-25 | 1984-03-29 | Bayer Ag, 5090 Leverkusen | MICROEMULSIONS |
DE3237814A1 (en) | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | WATER-FREE EMULSIONS AND USE THEREOF |
DE3315805A1 (en) | 1983-04-30 | 1984-11-08 | Bayer Ag, 5090 Leverkusen | Active substance compositions |
JPS6061535A (en) | 1983-08-24 | 1985-04-09 | エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト | Pharmaceutical composition |
FR2553661B1 (en) | 1983-10-19 | 1985-12-20 | Rhone Poulenc Sante | NEW PHARMACEUTICALLY ACCEPTABLE MICROEMULSIONS |
DE3406497A1 (en) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
GB8903804D0 (en) | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
DE3580717D1 (en) | 1984-08-02 | 1991-01-10 | Sandoz Ag | PHARMACEUTICAL APPLICATION OF (NVA) 2-CYCLOSPORINE. |
CH662944A5 (en) | 1984-10-18 | 1987-11-13 | Pier Luigi Prof Dr Luisi | PROCEDURE FOR THE PREPARATION OF BIOCOMPATIBLE REVERSE MICROCOMPATIBLES AND THEIR USE. |
DE3444893A1 (en) | 1984-12-08 | 1986-06-12 | Henkel KGaA, 4000 Düsseldorf | METHOD FOR PRODUCING FATTY ACID METHYL ESTERS |
JPS61249918A (en) | 1985-04-26 | 1986-11-07 | Yutaka Mizushima | Eye drops |
IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
US5023271A (en) | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
US4797272A (en) | 1985-11-15 | 1989-01-10 | Eli Lilly And Company | Water-in-oil microemulsions for cosmetic uses |
SE8601624D0 (en) * | 1986-04-11 | 1986-04-11 | Haessle Ab | NEW PHARMACEUTICAL PREPARATIONS |
SE457693B (en) | 1986-07-01 | 1989-01-23 | Drilletten Ab | COMPOSITION WITH REGULATED RELEASE WAS A BIOLOGICAL MATERIAL LOST OR DISPERSED IN AN L2 PHASE |
EP0256856A3 (en) | 1986-08-14 | 1989-01-11 | Synthetic Blood Corporation | A parenterally administrable composition |
DE3629386A1 (en) | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | GELATINE CAPSULES AND METHOD FOR THEIR PRODUCTION |
DE3707711A1 (en) | 1987-03-11 | 1988-09-22 | Hoechst Ag | OIL-IN-WATER EMULSIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
CA1301642C (en) | 1987-03-30 | 1992-05-26 | Howard Bernard Dawson | Chemical formulations |
US4798823A (en) | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
EP0296122B1 (en) * | 1987-06-17 | 1993-09-29 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
GB2206119B (en) | 1987-06-22 | 1990-10-31 | Merck & Co Inc | A new cyclosporin derivative with modified "8-amino acid" |
US4835002A (en) | 1987-07-10 | 1989-05-30 | Wolf Peter A | Microemulsions of oil in water and alcohol |
US4839342A (en) | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
KR920003601B1 (en) | 1987-09-03 | 1992-05-04 | 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 | Ocular cyclosporin composition |
HU205010B (en) | 1987-09-15 | 1992-03-30 | Sandoz Ag | Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
IL88076A (en) | 1987-10-28 | 1993-01-14 | Nippon Shinyaku Co Ltd | Fat emulsions as drug carriers |
US4914188A (en) | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
AU609242B2 (en) | 1988-01-29 | 1991-04-26 | Novartis Ag | Cyclosporin compositions |
CH679119A5 (en) | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
EP0361928B1 (en) | 1988-09-29 | 1994-04-27 | Shiseido Company Limited | Emulsified composition |
JPH0738771B2 (en) | 1989-01-17 | 1995-05-01 | 花王株式会社 | Liquid edible oil composition |
AU5157590A (en) | 1989-02-06 | 1990-08-24 | Abbott Laboratories | Pharmaceutical compositions for oral administration |
CH679277A5 (en) | 1989-02-09 | 1992-01-31 | Sandoz Ag | |
US4996193A (en) | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
JP2785981B2 (en) * | 1989-11-20 | 1998-08-13 | 株式会社資生堂 | Emulsion composition |
AU6785490A (en) | 1989-12-18 | 1991-06-20 | Kraft General Foods, Inc. | Low-saturate edible oils and transesterification methods for production thereof |
IL102236A0 (en) * | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
JP3065734B2 (en) * | 1991-08-27 | 2000-07-17 | 昭和電工株式会社 | Cinnamic acid derivative |
FR2683225B1 (en) | 1991-10-31 | 1993-12-31 | Gattefosse Sa | PROCESS FOR IMPROVING A GLYCEROLYZED OIL. |
US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
GB9208712D0 (en) * | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
EP0642332B1 (en) * | 1992-05-13 | 1997-01-15 | Sandoz Ltd. | Ophthalmic compositions containing a cyclosporin |
-
1993
- 1993-05-07 EP EP93909919A patent/EP0642332B1/en not_active Expired - Lifetime
- 1993-05-07 JP JP51984293A patent/JP3631490B2/en not_active Expired - Lifetime
- 1993-05-07 ES ES93909919T patent/ES2098739T3/en not_active Expired - Lifetime
- 1993-05-07 SG SG1996008974A patent/SG45449A1/en unknown
- 1993-05-07 AT AT93909919T patent/ATE147619T1/en active
- 1993-05-07 DE DE69307505T patent/DE69307505T2/en not_active Expired - Lifetime
- 1993-05-07 DK DK93909919.8T patent/DK0642332T3/en active
- 1993-05-07 WO PCT/EP1993/001123 patent/WO1993023010A1/en active IP Right Grant
- 1993-05-12 CN CN93107203A patent/CN1074932C/en not_active Expired - Lifetime
- 1993-06-08 TW TW082104550A patent/TW279801B/zh not_active IP Right Cessation
-
1994
- 1994-11-10 KR KR1019940704017A patent/KR100344083B1/en not_active IP Right Cessation
-
1996
- 1996-12-17 US US08/767,610 patent/US5951971A/en not_active Expired - Lifetime
-
1997
- 1997-04-01 GR GR970400664T patent/GR3022990T3/en unknown
-
1998
- 1998-04-23 HK HK98103406A patent/HK1004520A1/en not_active IP Right Cessation
-
2001
- 2001-08-27 US US09/939,967 patent/US6582718B2/en not_active Expired - Fee Related
-
2004
- 2004-09-10 JP JP2004264204A patent/JP2004346085A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4649047A (en) * | 1985-03-19 | 1987-03-10 | University Of Georgia Research Foundation, Inc. | Ophthalmic treatment by topical administration of cyclosporin |
EP0294239A1 (en) * | 1987-06-04 | 1988-12-07 | Sankyo Company Limited | Cyclosporin-containing pharmaceutical composition |
GB2211848A (en) * | 1987-12-21 | 1989-07-12 | Sandoz Ltd | Orthorhomic ciclosporin crystals |
FR2636534A1 (en) * | 1988-09-16 | 1990-03-23 | Sandoz Sa | PHARMACEUTICAL COMPOSITIONS BASED ON CYCLOSPORINS |
FR2638089A1 (en) * | 1988-10-26 | 1990-04-27 | Sandoz Sa | NOVEL OPHTHALMIC COMPOSITIONS BASED ON CYCLOSPORINE |
Non-Patent Citations (1)
Title |
---|
DATABASE WPIL Week 9315, Derwent Publications Ltd., London, GB; AN 93-121283 (15) * |
Cited By (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US6254885B1 (en) | 1995-08-25 | 2001-07-03 | Sangstat Medical Corporation | Oral cyclosphorin formulations |
US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
EP0868909A2 (en) * | 1997-03-14 | 1998-10-07 | Arturo Jimenez-Bayardo | Ophthalmic carrier solution |
EP0868909A3 (en) * | 1997-03-14 | 1999-09-08 | Arturo Jimenez-Bayardo | Ophthalmic carrier solution |
EP1142566A1 (en) * | 2000-04-07 | 2001-10-10 | Laboratoire Medidom S.A. | Compositions for ophtalmic use containing cyclosporin, hyaluronic acid and polysorbate |
US6677304B2 (en) | 2000-04-07 | 2004-01-13 | Laboratorie Medidom S.A. | Ophthalmic formulations |
US6953776B2 (en) | 2000-04-07 | 2005-10-11 | Laboratoire Medidom S.A. | Ophthalmic formulations |
US8846618B2 (en) | 2001-06-28 | 2014-09-30 | Novo Nordisk A/S | Stable formulation of modified GLP-1 |
WO2004096261A1 (en) * | 2003-05-02 | 2004-11-11 | Arturo Jimenez Bayardo | Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution |
US8614181B2 (en) | 2003-06-03 | 2013-12-24 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
US8114959B2 (en) | 2003-06-03 | 2012-02-14 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
WO2005049061A3 (en) * | 2003-11-20 | 2005-10-20 | Novo Nordisk As | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
EP3300721A1 (en) * | 2003-11-20 | 2018-04-04 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
AU2004290862B2 (en) * | 2003-11-20 | 2010-06-03 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
EP2394656A3 (en) * | 2003-11-20 | 2012-01-18 | Novo Nordisk A/S | Propylene Glycol-containing peptide formulations which are optimal for production and for use in injection devices |
US8114833B2 (en) | 2003-11-20 | 2012-02-14 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
KR101243648B1 (en) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
WO2005049061A2 (en) * | 2003-11-20 | 2005-06-02 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
US8710181B2 (en) | 2004-08-31 | 2014-04-29 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
US8748376B2 (en) | 2004-11-12 | 2014-06-10 | Novo Nordisk A/S | Stable formulations of peptides |
EP1889620A4 (en) * | 2005-06-09 | 2008-12-10 | Santen Pharmaceutical Co Ltd | Eye drop containing roflumilast |
EP1889620A1 (en) * | 2005-06-09 | 2008-02-20 | Santen Pharmaceutical Co., Ltd | Eye drop containing roflumilast |
RU2634267C2 (en) * | 2012-03-22 | 2017-10-24 | Лаборатуар Теа | Aqueous ophthalmic solution based on cyclosporin a |
US8969305B2 (en) | 2012-03-22 | 2015-03-03 | Laboratories Thea | Aqueous ophthalmic solution based on cyclosporin |
FR2988297A1 (en) * | 2012-03-22 | 2013-09-27 | Thea Lab | AQUEOUS OPHTHALMIC SOLUTION FROM CICLOSPORINE WITHOUT PRESERVATIVE |
WO2013140071A1 (en) * | 2012-03-22 | 2013-09-26 | Laboratoires Thea | Cyclosporin a-based aqueous ophthalmic solution |
KR20150100763A (en) * | 2012-12-19 | 2015-09-02 | 에스에이알코드 바이오사이언스 인코포레이티드 | Lfa-1 inhibitor formulations |
US11058677B2 (en) | 2012-12-19 | 2021-07-13 | Novartis Ag | LFA-1 inhibitor formulations |
EP3827823A1 (en) * | 2012-12-19 | 2021-06-02 | Novartis AG | Lfa-1 inhibitor formulations |
EP2934510A4 (en) * | 2012-12-19 | 2016-08-17 | Sarcode Bioscience Inc | Lfa-1 inhibitor formulations |
AU2013361579B2 (en) * | 2012-12-19 | 2018-05-24 | Bausch + Lomb Ireland Limited | LFA-1 inhibitor formulations |
KR101891144B1 (en) | 2012-12-19 | 2018-08-23 | 에스에이알코드 바이오사이언스 인코포레이티드 | Lfa-1 inhibitor formulations |
RU2713953C2 (en) * | 2014-07-18 | 2020-02-11 | Аллерган, Инк. | Suspension compositions of cyclosporine a for subconjunctival and periocular injection |
US10780048B2 (en) | 2014-07-18 | 2020-09-22 | Allergan, Inc. | Suspension compositions of cyclosporin A for subconjunctival and periocular injection |
AU2015289387B2 (en) * | 2014-07-18 | 2020-10-22 | Allergan, Inc. | Suspension compositions of cyclosporin A for subconjunctival and periocular injection |
WO2016011449A1 (en) * | 2014-07-18 | 2016-01-21 | Allergan, Inc. | Suspension compositions of cyclosporin a for subconjunctival and periocular injection |
WO2016012912A1 (en) | 2014-07-25 | 2016-01-28 | Imuneks Farma Ilac Sanayi Ve Ticaret A.S. | Stable preservative free ophthalmic formulations of opioid antagonists |
EP3329940A4 (en) * | 2015-07-29 | 2019-01-02 | Kukje Pharm. Ind. Co., Ltd | Non-irritant ophthalmic composition containing cyclosporin, and convenient preparation method |
CN109906085A (en) * | 2016-09-23 | 2019-06-18 | 诺瓦利克有限责任公司 | Ophthalmic composition containing cyclosporine |
CN109906085B (en) * | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | Ophthalmic compositions containing cyclosporin |
US11752198B2 (en) | 2017-08-24 | 2023-09-12 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2098739T3 (en) | 1997-05-01 |
DE69307505D1 (en) | 1997-02-27 |
JP2004346085A (en) | 2004-12-09 |
US20020045601A1 (en) | 2002-04-18 |
KR950701515A (en) | 1995-04-28 |
ATE147619T1 (en) | 1997-02-15 |
KR100344083B1 (en) | 2002-11-23 |
US6582718B2 (en) | 2003-06-24 |
HK1004520A1 (en) | 1998-11-27 |
JP3631490B2 (en) | 2005-03-23 |
DE69307505T2 (en) | 1997-07-24 |
TW279801B (en) | 1996-07-01 |
US5951971A (en) | 1999-09-14 |
GR3022990T3 (en) | 1997-07-30 |
EP0642332B1 (en) | 1997-01-15 |
EP0642332A1 (en) | 1995-03-15 |
SG45449A1 (en) | 1998-01-16 |
CN1074932C (en) | 2001-11-21 |
CN1084079A (en) | 1994-03-23 |
DK0642332T3 (en) | 1997-06-16 |
JPH07506579A (en) | 1995-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5951971A (en) | Ophthalmic compositions | |
JP6731039B2 (en) | Pharmaceutical composition for the treatment of dry eye syndrome | |
EP0759773B1 (en) | Lacrimal gland specific emulsions for topical application to ocular tissue | |
US6489335B2 (en) | Treatment of ocular disease | |
US6579901B2 (en) | Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye | |
US5766619A (en) | Pharmaceutical dosage form for ocular administration and preparation process | |
AU626928B2 (en) | Cyclosporin opthalmic compositions | |
JPH0216728B2 (en) | ||
HRP20000258A2 (en) | Topical ophthalmic preparations containing immunosuppressive agents | |
EP4025235A1 (en) | Ophthalmic composition for the treatment of uveitis | |
RU2434633C2 (en) | Pharmaceutical preparative forms of latrunculin | |
JPH0710701A (en) | Agent for entoptic perfusion and washing and preservative for eyeball |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993909919 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 331648 Country of ref document: US Date of ref document: 19941110 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019940704017 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1993909919 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 767610 Country of ref document: US Date of ref document: 19961217 Kind code of ref document: A |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993909919 Country of ref document: EP |